Gonugunta VK - Search Results

1

STING-associated vasculopathy develops independently of IRF3 in mice.

Warner JD, Irizarry-Caro RA, Bennion BG, Ai TL, Smith AM, Miner CA, Sakai T, Gonugunta VK, Wu J, Platt DJ, Yan N, Miner JJ. Warner JD, et al. Among authors: gonugunta vk. J Exp Med. 2017 Nov 6;214(11):3279-3292. doi: 10.1084/jem.20171351. Epub 2017 Sep 26. J Exp Med. 2017. PMID: 28951494 Free PMC article.

2

STING Activation by Translocation from the ER Is Associated with Infection and Autoinflammatory Disease.

Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan N. Dobbs N, et al. Among authors: gonugunta vk. Cell Host Microbe. 2015 Aug 12;18(2):157-68. doi: 10.1016/j.chom.2015.07.001. Epub 2015 Jul 30. Cell Host Microbe. 2015. PMID: 26235147 Free PMC article.

3

Trafficking-Mediated STING Degradation Requires Sorting to Acidified Endolysosomes and Can Be Targeted to Enhance Anti-tumor Response.

Gonugunta VK, Sakai T, Pokatayev V, Yang K, Wu J, Dobbs N, Yan N. Gonugunta VK, et al. Cell Rep. 2017 Dec 12;21(11):3234-3242. doi: 10.1016/j.celrep.2017.11.061. Cell Rep. 2017. PMID: 29241549 Free PMC article.

4

Chronic innate immune activation of TBK1 suppresses mTORC1 activity and dysregulates cellular metabolism.

Hasan M, Gonugunta VK, Dobbs N, Ali A, Palchik G, Calvaruso MA, DeBerardinis RJ, Yan N. Hasan M, et al. Among authors: gonugunta vk. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):746-751. doi: 10.1073/pnas.1611113114. Epub 2017 Jan 9. Proc Natl Acad Sci U S A. 2017. PMID: 28069950 Free PMC article.

5

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK. Raj GV, et al. Among authors: gonugunta vk. Elife. 2017 Aug 8;6:e26857. doi: 10.7554/eLife.26857. Elife. 2017. PMID: 28786813 Free PMC article.

6

Therapeutic significance of estrogen receptor β agonists in gliomas.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK. Sareddy GR, et al. Among authors: gonugunta vk. Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21. Mol Cancer Ther. 2012. PMID: 22442308 Free PMC article.

7

The social network of PELP1 and its implications in breast and prostate cancers.

Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV. Gonugunta VK, et al. Endocr Relat Cancer. 2014 Aug;21(4):T79-86. doi: 10.1530/ERC-13-0502. Epub 2014 May 23. Endocr Relat Cancer. 2014. PMID: 24859989 Review.

8

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Gonugunta VK, Sareddy GR, Krishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK. Gonugunta VK, et al. Mol Cancer Ther. 2014 Jun;13(6):1578-88. doi: 10.1158/1535-7163.MCT-13-0877. Epub 2014 Mar 31. Mol Cancer Ther. 2014. PMID: 24688046 Free PMC article.

9

KDM1 is a novel therapeutic target for the treatment of gliomas.

Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK. Sareddy GR, et al. Among authors: gonugunta vk. Oncotarget. 2013 Jan;4(1):18-28. doi: 10.18632/oncotarget.725. Oncotarget. 2013. PMID: 23248157 Free PMC article.

10

HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.

Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B. Bugide S, et al. Among authors: gonugunta vk. Cell Oncol (Dordr). 2017 Apr;40(2):133-144. doi: 10.1007/s13402-016-0308-2. Epub 2016 Dec 30. Cell Oncol (Dordr). 2017. PMID: 28039608

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page